Smeland, Olav B. http://orcid.org/0000-0002-3761-5215
Frei, Oleksandr http://orcid.org/0000-0002-6427-2625
Shadrin, Alexey
O’Connell, Kevin http://orcid.org/0000-0002-6865-8795
Fan, Chun-Chieh http://orcid.org/0000-0001-9437-2128
Bahrami, Shahram
Holland, Dominic
Djurovic, Srdjan http://orcid.org/0000-0002-8140-8061
Thompson, Wesley K. http://orcid.org/0000-0002-1148-1976
Dale, Anders M. http://orcid.org/0000-0002-6126-2966
Andreassen, Ole A. http://orcid.org/0000-0002-4461-3568
Funding for this research was provided by:
National Institutes of Health (NS057198, EB00790)
National Institute on Drug Abuse (U24DA041123)
The Research Council of Norway (229129, 213837, 248778, 223273, 249711)
Helse Sør-Øst RHF (2017-112)
Stiftelsen Kristian Gerhard Jebsen (SKGJ-2011-36)
Article History
Received: 20 November 2018
Accepted: 8 August 2019
First Online: 13 September 2019
Compliance with ethical standards
:
: OA.A. has received speaker’s honorarium from Lundbeck and is a consultant for Healthlytix. C.C.F. is under employment of Multimodal Imaging Service, dba Healthlytix, in addition to his research appointment at the University of California, San Diego. A.M.D. is a founder of and holds equity interest in CorTechs Labs and serves on its scientific advisory board. He is also a member of the Scientific Advisory Board of Healthlytix and receives research funding from General Electric Healthcare (GEHC). The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. Remaining authors have no conflicts of interest to declare.